Happy New Year! Its another January and we’re taking stock of last year and pondering the one before us.
Reflecting on the Life Science landscape, there are a number of good reasons to be optimistic about where things are today.
1. Exits: Real innovation won in the M&A marketplace for venture-backed biotechs. A number of great deals with attractive multiples were closed in 2011 for companies with innovative assets in hot areas of medicine and science: e..g, B-raf at Plexxikon, PI3Kd at Calistoga, LPA at Amira, dual PI3K/mTor at Intellikine, oncolytic viruses at BioVex, and most recently Astofase Alfa at Enobia. I expect that in 2012 this theme will accelerate with a number of exciting innovative biotechs getting acquired.
To read the full, original article click on this link: Biotech's Glass Half Full for 2012 - Forbes
